Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Symmetry Medical ( SMA - Analyst Report ) , an instrument supplier to orthopedic devices makers, has introduced a novel arm positioning system geared for improving arthroscopic and open surgical elbow surgeries. The Indiana-based company has launched the new product dubbed ElbowLOC through its fully-owned subsidiary Specialty Surgical Instrumentation (“SSI”).
The ElbowLOC system is a positioning device that uses supine (lying face up) patient positioning for surgeries of the elbow. The new system is now available for sale under the “ACCESS” arthroscopy brand through SSI's website.
The ElbowLOC offers surgeons a stable platform for elbow surgeries and efficient patient positioning. Moreover, it lessens procedural times and eliminates the need for intra-operative arm traction devices. The launch of this innovative system is in tandem with Symmetry’s strategy to boost sales of its proprietary medical devices.
Symmetry is the largest OEM provider of orthopedic implants and instruments to orthopedic devices manufacturers. Its major customers include Johnson & Johnson’s ( JNJ - Analyst Report ) DePuy, Stryker ( SYK - Analyst Report ) and Zimmer Holdings ( ZMH - Analyst Report ) . The acquisition of privately-held electrosurgical instruments maker Olsen Medical has enabled the company to further diversify its product range and boost direct hospital business.
Symmetry’s “Total Solutions” approach has differentiated it from the rivals and provided a substantial growth opportunity. The company is investing in revamping its management structure and enhancing customer collaboration, which should support growth. Moreover, Symmetry should benefit from higher demand for its solutions as its major customers ramp up spending and accelerate product launches.
However, Symmetry still faces price and procedure volume pressure on the orthopedic front. Also, the company’s high spending may continue to weigh on its bottom line. Currently we are Neutral on the stock.
Read the full reports :
Analyst Report on SMA
Analyst Report on SYK
Analyst Report on ZMH
Analyst Report on JNJ